Results 41 to 50 of about 6,071 (199)
Medicinal Research Reviews, Volume 46, Issue 3, Page 672-712, May 2026.ABSTRACT Respiratory syncytial virus (RSV) is a common virus that causes respiratory infections, posing a serious threat, particularly to infants, the elderly, and individuals with compromised immune systems. As the leading cause of lower respiratory tract infections (LRTIs) in infants, RSV is responsible for millions of cases worldwide each year.
Jie Shi +6 more
wiley +1 more source
BMC Pediatrics, 2019 Background Palivizumab prophylaxis for the human respiratory syncytial virus (HRSV) has been reported to reduce the risk of hospital admissions related to HRSV in children with congenital heart disease (CHD). These children are at high risk of developing
Roseane Porfírio de Souza +3 more
doaj +1 more source
Paediatric and Perinatal Epidemiology, Volume 40, Issue 4, Page 484-496, May 2026.ABSTRACT Background Palivizumab was introduced in Canada in 1998 as a publicly funded programme to reduce respiratory syncytial virus (RSV) disease in high‐risk children. Severe early‐life RSV infections are associated with increased asthma risk. Thus, palivizumab may also indirectly reduce paediatric asthma.
Kimberley A. Foley +9 more
wiley +1 more source
Population Pharmacokinetics of Clesrovimab in Preterm and Full‐Term Infants
Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 1036-1046, April 2026.Clesrovimab is a half‐life extended monoclonal antibody targeting the respiratory syncytial virus fusion protein. Three studies (phase Ib/IIa [MK‐1654‐002], phase IIb/III [CLEVER], and phase III [SMART]) were conducted to evaluate the efficacy, safety, and pharmacokinetics (PK) of clesrovimab in infants.
Ziheng Hu +8 more
wiley +1 more source
Palivizumab Exposure and the Risk of Autoimmune Disease:A Cross-National Cohort Study
, 2016 BACKGROUND: Treatment with biologic pharmaceuticals may be associated with an increased risk of immune-mediated disease. Palivizumab is a humanized monoclonal antibody designed to provide passive immunity against respiratory syncytial virus infection ...
Linder, Marie +6 more
core +1 more source
Influenza and Other Respiratory Viruses, Volume 20, Issue 3, March 2026.ABSTRACT Background From 2016 to 2018, the World Health Organization (WHO) initiated a global RSV surveillance pilot program in 14 countries, expanding to 25 countries from 2019 to 2023. As part of this, a sequencing program was introduced to improve the understanding of RSV global genetic diversity prior to and following the introduction of ...
Obadiah Kenji +12 more
wiley +1 more source
Palivizumab: A debate about funding
Journal of Paediatrics and Child Health, 2010 AbstractA clinician and the chair of the hospital drug committee debate the merits of the use of palivizumab as prophylaxis against respiratory syncytial virus infection for a preterm baby with oxygen‐dependent, chronic lung disease and discuss the issue of public funding of palivizumab.
Fitzgerald, Dominic +2 more
openaire +3 more sources
Immunity, Inflammation and Disease, Volume 14, Issue 2, February 2026.ABSTRACT Background Viral‐respiratory infections are the most prevalent illness among humans. A viral infection affecting lower respiratory tract infections (LRTI) is a critical health concern worldwide. The COVID‐19 pandemic has significantly impacted respiratory health, particularly in individuals with asthma.
Mandana Akhavan +2 more
wiley +1 more source
Pediatric Pulmonology, Volume 61, Issue 2, February 2026.ABSTRACT Introduction Bronchiolitis is the leading cause of infant hospitalizations worldwide, primarily driven by respiratory syncytial virus (RSV). Methods This multicenter retrospective comparative study assessed the impact of immunoprophylaxis with nirsevimab against RSV on bronchiolitis‐related hospitalizations in Italy during the 2024–2025 winter
Sergio Ghirardo +28 more
wiley +1 more source
Biotechnology Progress, Volume 42, Issue 1, January/February 2026.Abstract Key hydrodynamic‐related parameters such as volumetric power input (P/V), impeller configuration, aeration strategy, and maximum gas sparge rate, as well as an appropriate feeding strategy, must be carefully selected to improve production yields in bioreactor.
Lucas Lemire +5 more
wiley +1 more source